Table 2.
Demographic, Clinical, and Neuropsychological (Level II) Characteristics of PD Patients (n = 102) and NC (n = 74).
| PD (PD-NC + PD-MCI) | NC | P | |
|---|---|---|---|
| Age, years, M (SD), Mdn | 60.47 (8.54), 63 | 61.38 (10.07), 63 | .436 |
| Education, years, M (SD), Mdn | 13.94 (2.96), 13 | 14.30 (2.53), 13 | .156 |
| Gender (% male) | 67 | 47 | .016a |
| Ethnicity (% Caucasian) | 100 | 100 | ns |
| Language (% Czech) | 100 | 100 | ns |
| Duration of PD, years, M (SD), Mdn | 11.06 (5.45), 11 | — | — |
| UPDRS-III (ON), M (SD), Mdn | 13.82 (10.26), 13.50 | — | — |
| Hoehn/Yahr stage, M (SD), Mdn | 2.04 (0.64), 2 | — | — |
| Medication (LEDD), M (SD), Mdn | 1275.40 (582.93), 1172.50 | — | — |
| MoCA-CZ, M (SD), Mdn | 25.12 (3.18), 26 | 26.59 (2.29), 27 | .001 (.004) |
| s-MoCA-CZ, M (SD), Mdn | 12.16 (2.51), 12 | 13.18 (1.90), 13 | .004 (.009) |
Note. LEDD = levodopa equivalent daily doses; UPDRS = Unified Parkinson’s Disease Rating Scale; MMSE = Mini-Mental State Examination Czech version; PD = Parkinson’s disease; PD-NC = Parkinson’s disease with normal cognition; ns = nonsignificant result; MoCA = Montreal Cognitive Assessment; MoCA-CZ = Montreal Cognitive Assessment Czech version; s-MoCA-CZ = short version MoCA-CZ; IPMDS = International Parkinson and Movement Disorder Society; PD-MCI = Parkinson’s disease with mild cognitive impairment, p Value is based on Mann-Whitney U test due to nonnormal distribution (or on independent samples t test in parenthesis). Data represent means or percentages, standard deviations, and medians. IPMDS PD-MCI battery domains, raw scores for the neuropsychological tests are provided.
χ2 test for independence (with Yates Continuity Correction).